Navigating medical billing for biologic drugs often feels like solving a puzzle where the pieces change shape every year. If you administer or prescribe romosozumab-aqqg, known by the brand name Evenity, having the correct coding information is not just about administrative tidiness. It directly impacts reimbursement, patient access, and compliance.
This article serves as a stable, reliable reference for the upcoming year. We will cover the precise codes, common pairings, payer-specific nuances, and documentation essentials for Evenity in 2026.
We focus strictly on confirmed patterns and official coding conventions. We do not deal in rumors or leaked data. The goal is to give you a clear, actionable roadmap for clean claims.
Understanding Evenity and Its Coding Landscape
Evenity stands apart from other osteoporosis treatments. Unlike oral bisphosphonates, it is a biologic agent with a unique mechanism that both builds bone and reduces resorption. For billing professionals, this means it lives in a specific category of medical codes reserved for injectable drugs in a clinical setting.
Most payers classify Evenity as a medical benefit rather than a pharmacy benefit. This classification is the first critical concept to grasp. Why does it matter? Because a pharmacy benefit claim uses NDC codes and goes through a PBM, while a medical benefit claim requires HCPCS codes and goes through a medical claims processor.
Since Evenity requires two subcutaneous injections once a month in a healthcare setting, the medical benefit pathway dominates. Understanding this prevents the most common denial: filing to the wrong payer portal.
The Dual-Injection Reality
A complete dose of Evenity consists of two separate prefilled syringes administered one after the other. This clinical fact creates a coding requirement: you must report two units of the drug code. Failing to account for both units will result in underpayment exactly half of what you are owed. This simple oversight costs clinics thousands of dollars annually.
The Primary HCPCS Code for Evenity in 2026
The permanent, product-specific HCPCS Level II code for Evenity is J3111. This code represents 0.5 mg of romosozumab-aqqg. We expect this code to remain active and unchanged for 2026. Permanent J-codes, once assigned by the CMS HCPCS Workgroup, do not change annually unless the product’s dosing or FDA approval shifts significantly.
No reliable evidence suggests a code change for J3111 in 2026. Medicare and commercial payers have fully transitioned from the miscellaneous code (J3590) that some clinics used during Evenity’s initial launch window. For at least five years, J3111 has been the national standard.
Correct Unit Calculation
The math behind proper billing is straightforward but non-negotiable. Each prefilled syringe of Evenity contains 105 mg of romosozumab in 1.17 mL of solution. The HCPCS descriptor for J3111 defines one unit as 0.5 mg. To determine the number of units per syringe, you divide 105 mg by 0.5 mg, which equals 210 units.
For the full monthly dose of two syringes, you bill 420 units. This number often startles new billing staff because it is unusually high. Unlike a typical injection code that might use 1 or 10 units, biologics often require large unit counts to match the drug’s potency measurement.
Here is the exact claim line logic:
- One syringe: J3111 x 210 units
- Full dose (two syringes): J3111 x 420 units
Submitting 420 units allows the payer to calculate payment based on the total milligrams administered, multiplied by the contracted or ASP-based rate per unit. Always verify that your practice management system can handle unit quantities in the hundreds without triggering an edit.
Important Note: Under no circumstances should you bill 2 units with the assumption that “2” represents two syringes. The unit field always refers back to the HCPCS descriptor increment. Billing 2 units would claim you administered only 1 mg of drug, inviting an immediate denial or a severe underpayment that cannot be recovered without a corrected claim.
NDC Code Reporting Requirements
Even though J3111 is the primary HCPCS code, many payers also mandate reporting the National Drug Code on professional claims. This requirement often appears in the comment field or a specific electronic loop on the 837P transaction.
The NDC for Evenity is tied to its packaging. For the prefilled syringe carton, the most common NDC used in outpatient settings is 55513-880-01 for the individual syringe. Some payers may require the carton NDC, 55513-880-02, which contains two syringes. Always check your payer’s billing guide to confirm which NDC level they expect.
Including an accurate NDC provides an extra layer of audit protection. When the NDC and the J-code align to describe the same product and quantity, automated edits flag far fewer claims. This small step significantly reduces administrative friction.
Administration CPT Codes: The Injection Partner
Drug codes cover the medication itself. The work of administering the injection requires a separate CPT code from the American Medical Association’s Category I set. For Evenity, the route of administration is subcutaneous, and the typical injection burden is low-complexity.
In 2026, the correct administration code for a subcutaneous injection remains 96372. This code describes a therapeutic, prophylactic, or diagnostic injection administered subcutaneously or intramuscularly.
Some practices serving complex patients might document a higher level of injection service, but this is exceptionally rare for a simple subcutaneous shot. Using 96372 reflects standard care.
Billing for Two Injections
Since the full Evenity dose requires two separate needle sticks at two different sites, you bill for two injection procedures. The appropriate modifier to distinguish the two sites and avoid a duplicate service denial is -59 (Distinct Procedural Service) or the more specific -XU (Unusual Non-Overlapping Service).
Your claim lines for the full service would appear as follows:
- J3111 x 420 units (drug)
- 96372 x 1 (first injection)
- 96372-59 or 96372-XU x 1 (second injection, distinct site)
Document the exact anatomical location of each injection clearly in the medical record. For example, note “left abdomen” and “right abdomen” or “left thigh” and “right thigh.” Clear site documentation validates the modifier and protects against payer recoupment during post-payment review.
Evenity Billing in the Hospital Outpatient Setting
The coding logic shifts if Evenity is administered in a hospital outpatient department. Rather than a physician office claim on a CMS-1500, the hospital files a UB-04 claim. The revenue code becomes a critical field.
In the hospital setting, J3111 remains the HCPCS code, but the claim requires a revenue code to categorize the service. The most appropriate revenue code is 0636 (Drugs Requiring Detailed Coding). Some facilities may use 0250 (General Pharmacy), but 0636 offers greater specificity and fewer payer rejections.
The unit calculation does not change. 420 units still represent the full dose. However, hospital chargemasters often contain automated unit multipliers. A common error occurs when the chargemaster multiplies the J-code units by the number of syringes again, double-counting the dosage. Always audit the charge description master (CDM) build carefully to ensure it accurately reflects the 210-unit-per-syringe logic without redundant multipliers.
Hospital outpatient claims also require a status indicator assignment from CMS. Evenity typically falls under status indicator K, meaning the drug is paid separately under OPPS when billed with an appropriate administration service. This separate payment status makes correct coding even more financially important.
Medicare Administrative Contractor (MAC) Variations
While the code itself remains national, local Medicare Administrative Contractors sometimes publish Local Coverage Determinations (LCDs) or billing articles that refine instructions. Before submitting your first 2026 claim, review your MAC’s website for any Evenity-specific articles.
Key elements MACs often address include:
- Diagnosis code requirements: Most MACs require an ICD-10 code reflecting postmenopausal osteoporosis with a high risk of fracture. Codes like M81.0 (Age-related osteoporosis without current pathological fracture) or M81.8 (Other osteoporosis) paired with a documented fragility fracture history often satisfy medical necessity.
- Frequency limitations: MACs expect 12 monthly doses per treatment course. Claims beyond 13 doses in a 12-month period will almost certainly trigger a medical review.
- Prior authorization mandates: Evenity is a frequent target for prior authorization, even in traditional Medicare. Check your MAC’s specific PA list, which may expand in 2026.
Ignoring local guidance invites denials even when the national coding is perfect. Treat your MAC’s website as a living resource.
Commercial Payer and Medicare Advantage Considerations
Commercial payers and Medicare Advantage plans follow the same core coding rules, but they introduce layers of complexity through their own medical necessity criteria and prior authorization processes.
The most common variation involves site-of-service restrictions. Many commercial plans mandate that Evenity injections occur in a physician’s office or an infusion center, not a hospital outpatient department, because the allowed amount is significantly lower in an office setting. They may also require a specific diagnosis code and documentation of prior bisphosphonate failure or intolerance before approving the biologic.
When verifying benefits, ask the payer representative three specific questions:
- “Do you require prior authorization for J3111?”
- “What ICD-10 codes satisfy your medical necessity criteria for Evenity?”
- “Is there a site-of-service restriction or preferred provider network for drug administration?”
Document the answers, including the reference number for the call, directly in the patient’s account notes. This documentation saves hours of appeal work later.
The Self-Administered Drug Exclusion
A subtle but dangerous trap exists in some commercial policies: the self-administered drug exclusion. Some plans deny injectable drugs under the medical benefit if a layperson could theoretically administer them at home. Evenity’s once-monthly injection schedule and the existence of a prefilled syringe sometimes trigger this exclusion.
Your strongest defense is the FDA Risk Evaluation and Mitigation Strategy (REMS) and prescribing information, which states that Evenity should be administered by a healthcare professional. Keep this documentation ready for any appeal. A letter of medical necessity emphasizing the clinical monitoring required during administration can also overturn such denials.
Prior Authorization Best Practices for 2026
The prior authorization landscape for Evenity remains stringent. Payers monitor this drug closely due to its cost and the existence of cheaper osteoporosis alternatives.
A gold-standard prior authorization submission includes:
- A completed, signed attestation form specific to the payer.
- Clinical notes documenting the osteoporosis diagnosis and risk level.
- A DXA scan result, typically showing a T-score of -2.5 or lower, or a history of a fragility fracture.
- Documentation of contraindication, intolerance, or inadequate response to at least one oral bisphosphonate.
- A detailed treatment plan specifying the planned 12-month course.
Submitting an incomplete packet is the single largest contributor to initial denials. A checklist system within your practice, where a dedicated staff member verifies each required document before faxing or uploading the request, improves first-pass approval rates significantly.
Table: Common Evenity Coding Denials and Resolutions
Use this quick-reference table to troubleshoot rejections and denials.
| Denial Reason | Root Cause | Resolution |
|---|---|---|
| Units exceed maximum allowable | Payer expects 210 units, not 420 | Appeal with the package insert showing 105 mg per syringe; clarify two syringes equal one dose |
| Duplicate injection service | Modifier -59 missing on second 96372 | Submit corrected claim with -59 or -XU on the second administration line |
| Service not covered under medical benefit | Plan uses pharmacy benefit for Evenity | Contact PBM for coverage; if medical benefit applies, file appeal with NDC and medical necessity letter |
| Diagnosis inconsistent with procedure | ICD-10 code not specific to osteoporosis | Amend code to M81.0 or M80.08xA with supporting clinical documentation |
| Prior authorization missing | Payer changed PA requirements for the new year | Retrospective authorization request if plan allows; implement a calendar review of all PA requirements each December |
| Code invalid for date of service | Practice management system not updated with J3111 | Update code file; never revert to J3590 as permanent J-code already exists |
Detailed Walkthrough: Submitting a Clean Evenity Claim
Let’s translate all the guidance into a practical, step-by-step claim assembly process for a typical physician office visit.
Step 1: Confirm Demographic and Eligibility Data
Pull the patient’s active insurance card. Run an eligibility transaction through your clearinghouse portal or the payer’s provider portal. Screenshot or print the result showing active medical coverage and the patient’s responsibility amount.
Step 2: Verify Active Prior Authorization
Check your internal tracking log. The authorization number must be valid on the date of service. Note the expiration date; many PAs for Evenity last six months and require a mid-course renewal.
Step 3: Code the Diagnosis
Link the most specific ICD-10 code to both the drug and the administration lines. If the patient has age-related osteoporosis with a current vertebral fracture, use M80.08xA. If the osteoporosis is drug-induced, use the appropriate secondary code. Precision here prevents medical necessity denials.
Step 4: Add the Drug Line
Enter HCPCS J3111. Set units to 420. If your software has an NDC field, enter 55513-880-01 and set the NDC unit qualifier and quantity correctly (often “ML” and 2.34 for the total volume). Verify that the charge amount, if manually set, reflects your practice’s contracted rate or a reasonable fee schedule amount.
Step 5: Add the Administration Lines
Enter 96372 for the first injection. Link it to diagnosis pointer 1. Enter 96372-59 for the second injection. Ensure each line has the same diagnosis pointers. Some practices also append a -25 modifier to the evaluation and management service if a significant, separately identifiable office visit occurred. Only append -25 if the documentation fully supports it.
Step 6: Complete the Documentation Puzzle
Before submitting the claim, open the corresponding clinical note. Confirm that it includes:
- The order for Evenity with the dose in mg (210 mg total).
- The route (subcutaneous).
- The specific injection sites (e.g., “right lower quadrant abdomen” and “left lower quadrant abdomen”).
- The lot number and expiration date of the administered syringes.
- Patient tolerance and any immediate adverse reactions.
Step 7: Submit and Monitor
Transmit the claim. Within 72 hours, review your clearinghouse reports for any front-end rejections. If the claim passes to the payer, log the claim number and track its status weekly. For Medicare claims, use the Direct Data Entry (DDE) system or your clearinghouse’s status tool to confirm it moves from “received” to “in process” to “finalized/paid.”
The Evolving Audit Landscape
Medicare Advantage plans and Recovery Audit Contractors (RACs) have sharpened their focus on biologic drug billing. Evenity, with its high unit count and monthly frequency, presents a target.
Auditors typically request:
- The signed physician order.
- A completed medication administration record.
- Proof of medical necessity (DXA scan report).
- Buy-and-bill inventory logs matching the specific lot number billed.
Maintain a binder or secure digital folder for each Evenity patient containing these documents from day one. During an audit, pulling a single comprehensive file immediately reduces the burden on your staff and demonstrates organizational competence.
Inventory reconciliation deserves special attention. Auditors will cross-reference the lot number on the claim or the medication administration record against your purchase invoices. Any mismatch suggests the billed drug may not have been the drug actually purchased or administered. A simple spreadsheet tracking lot number, date received, date administered, patient name, and remaining stock eliminates this risk.
ICD-10 Coding Precision for Osteoporosis
Diagnosis coding is the silent partner of a successful Evenity claim. The most commonly used codes include:
- M81.0 – Age-related osteoporosis without current pathological fracture. This is the most frequent code for patients who have not yet fractured but meet T-score criteria.
- M80.08xA – Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture.
- M80.85xA – Other osteoporosis with current pathological fracture, femur, initial encounter.
- Z79.83 – Long-term current use of bisphosphonates (removed from active problem list once Evenity begins). This code becomes secondary to document history if relevant.
A common error involves coding a “history of” fracture when the fracture is still healing. A current pathological fracture requires an active code from the M80 series, not a Z-code for history. Misfiling a current fracture as a history code suggests lower acuity and can jeopardize medical necessity approval.
Preparing Your Practice for 2026: A Month-by-Month Calendar
Coding stability does not mean zero maintenance. Smart practices implement a structured update rhythm.
January: Update your charge description master and EMR quick lists to confirm J3111 is active. Run test claims to major payers to catch any early-year rejections.
April: Review Q1 denial trends. If a particular payer shows a pattern of “J3111 not covered” despite active PA, schedule a provider relations call.
July: Conduct a mid-year documentation audit. Pull five Evenity charts at random. Check that every administration includes a signed order, two-site documentation, and lot number. Address gaps immediately.
October: Begin prior authorization renewals for patients starting their 12th month of treatment in December or January. Overlap the PA periods to prevent treatment gaps.
December: Download all new and updated payer policies for the coming year. Update your internal quick-reference payer grid with any prior authorization list changes, new diagnosis requirements, or NDC reporting mandates.
This rhythm transforms annual maintenance from a frantic scramble into a manageable routine.
Table: Quick-Reference Evenity Billing Matrix for 2026
| Billing Element | Physician Office (CMS-1500) | Hospital Outpatient (UB-04) |
|---|---|---|
| Drug Code | J3111 | J3111 |
| Units per Dose | 420 | 420 |
| Unit Definition | Per 0.5 mg | Per 0.5 mg |
| Administration Code | 96372, 96372-59 | C-codes or 96372 depending on APC packaging |
| Revenue Code (if applicable) | N/A | 0636 |
| Modifier for Second Admin | -59 or -XU | -59 or -XU |
| NDC (Common) | 55513-880-01 | 55513-880-01 |
| Diagnosis Pointer | Osteoporosis ICD-10 | Osteoporosis ICD-10 |
Navigating the Transition from Bisphosphonates to Evenity
Patients often begin Evenity after years on an oral bisphosphonate like alendronate. This transition creates a documentation opportunity that directly supports medical necessity.
In your treatment note, clearly state the reason for the change. A sentence as simple as, “Patient has been on alendronate for three years with declining T-scores at the lumbar spine and a new fragility fracture of the distal radius; transitioning to anabolic therapy with Evenity,” provides a concise, bulletproof narrative.
This narrative blocks the most common payer challenge: that a cheaper alternative has not been tried. The chart explicitly acknowledges the previous therapy and its failure, satisfying step therapy requirements without a separate appeal.
The Role of Advanced Beneficiary Notices (ABNs)
For Medicare patients, an ABN becomes necessary when you suspect Evenity may not be covered due to frequency limits, lack of medical necessity, or an off-label diagnosis. The ABN must be specific, listing the service as “Evenity injection (J3111) and administration (96372)” and giving a clear, plain-language reason why Medicare might deny.
A vague ABN offers no financial protection. A properly executed ABN allows you to bill the patient for the service if Medicare denies. Without it, you must write off the charge. Train your front desk and clinical staff to recognize the ABN triggers for biologic drugs and keep blank forms readily accessible.
Answering Patient Financial Questions Confidently
Patients on Evenity often have questions about cost. While you cannot quote exact out-of-pocket amounts without running the claim, you can explain the structure clearly.
Tell patients that the claim includes three parts: the drug itself, the first injection, and the second injection. Their insurance will apply each part to their deductible and coinsurance or copay. If they have a secondary insurance, it may cover the remaining amount. Manufacturer copay assistance programs for Evenity can also help commercially insured patients cover their share of the cost.
Providing this transparent explanation reduces anxiety and builds trust. It also prevents the billing office from receiving angry calls when the patient receives an Explanation of Benefits showing three separate line items.
Table: Documentation Checklist for Audit-Ready Evenity Records
Maintain the following items in every Evenity patient record.
| Document | Required | Frequency |
|---|---|---|
| Signed Physician Order | Yes | Every 12-dose treatment course |
| Current DXA Scan (within 2 years) | Yes | Biannually, or more often if clinically indicated |
| Prior Authorization Approval Letter | Yes | Every authorization period |
| Medication Administration Record with Lot # and Sites | Yes | Every visit |
| Patient Encounter Note with Diagnosis and Response | Yes | Every visit |
| Inventory Log Matching Lot # to Purchase Invoice | Yes | Ongoing, reconciled monthly |
| Signed ABN (if applicable) | Conditional | When frequency or medical necessity is uncertain |
| Insurance Eligibility Verification | Yes | Every visit |
The Future of Evenity Coding and Reimbursement
Current indicators suggest stability for J3111 through 2026 and beyond. CMS continues to refine its ASP payment methodology for Part B drugs, which directly impacts Evenity’s reimbursement rate quarterly. Practices should review the quarterly ASP Drug Pricing Files for updates to the allowed amount for J3111. These small fluctuations affect revenue, especially on a high-unit drug.
The broader industry conversation about moving biologics from medical to pharmacy benefits under Medicare remains active. If such a policy ever advances, the coding landscape would shift dramatically, potentially requiring NDC-level billing through a PBM even for Part B patients. For now, however, the medical benefit and J3111 remain the standard. Staying vigilant through trade association updates and CMS rulemaking alerts is the best defense against surprise changes.
Building an Internal Training Module
A high-performing billing team thrives on consistent education. Create a five-minute training video or a printable quick card for all new employees that covers:
- The definition of J3111 and its unit structure.
- The two-syringe, 420-unit mandate.
- The correct administration codes and modifier.
- A screenshot of a correctly formatted claim.
- A list of the top three denials and their fixes.
Refreshing this training annually, even for experienced staff, ensures no one drifts into bad habits. A simple quiz at the end of the session confirms understanding and identifies gaps.
Conclusion
Accurate Evenity billing in 2026 centers on J3111, precise 420-unit calculations for the double-injection dose, and tight partnerships between clinical and coding teams. Payer rules may differ, but the national coding foundation stays firm. Good documentation and a prior authorization routine turn predictable denials into preventable ones.
Frequently Asked Questions (FAQ)
Q: What is the CPT code for Evenity in 2026?
A: Evenity uses the HCPCS Level II code J3111, which represents 0.5 mg of romosozumab-aqqg. This permanent code remains valid for 2026.
Q: How many units of J3111 should I bill for one monthly dose?
A: You must bill 420 units. Each syringe contains 105 mg, and with a unit defined as 0.5 mg, that equals 210 units per syringe. Two syringes equal a full dose of 420 units.
Q: Do I need a separate administration code for Evenity injections?
A: Yes. You bill CPT 96372 for the first subcutaneous injection and 96372 with a -59 or -XU modifier for the second, distinct injection.
Q: Does Evenity billing change if we administer it in a hospital outpatient department?
A: The HCPCS code J3111 and the 420-unit calculation remain the same. However, you file the claim on a UB-04 with revenue code 0636 instead of a CMS-1500.
Q: What diagnosis code supports medical necessity for Evenity?
A: ICD-10 code M81.0 (age-related osteoporosis without current pathological fracture) is frequently used. Codes from the M80 series, indicating osteoporosis with a current pathological fracture, provide even stronger support.
Q: Will Medicare cover Evenity without a prior authorization?
A: Many Medicare Administrative Contractors now require prior authorization for Evenity. Check your local MAC’s published list, as this requirement evolves each year.
Q: How can I find the exact Medicare payment rate for J3111?
A: CMS publishes the ASP Drug Pricing Files quarterly. The file lists the payment allowance limit for Part B drugs, including J3111, updated every calendar quarter.
Additional Resource
For the most current Medicare payment rates and coding updates for J3111, consult the official CMS ASP Drug Pricing Files page. This government resource is the authoritative source for reimbursement limits.
